KR920009796A - 3-아미도인돌릴 유도체 - Google Patents
3-아미도인돌릴 유도체 Download PDFInfo
- Publication number
- KR920009796A KR920009796A KR1019910019414A KR910019414A KR920009796A KR 920009796 A KR920009796 A KR 920009796A KR 1019910019414 A KR1019910019414 A KR 1019910019414A KR 910019414 A KR910019414 A KR 910019414A KR 920009796 A KR920009796 A KR 920009796A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- alkyl
- hydrogen
- substituted
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 32
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 18
- 150000002431 hydrogen Chemical group 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 5
- 150000003018 phosphorus compounds Chemical class 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 2
- 230000003042 antagnostic effect Effects 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 239000003257 excitatory amino acid Substances 0.000 claims 2
- 230000002461 excitatory amino acid Effects 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 150000003536 tetrazoles Chemical class 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000000049 anti-anxiety effect Effects 0.000 claims 1
- 230000003556 anti-epileptic effect Effects 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Paints Or Removers (AREA)
- Medicinal Preparation (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (26)
- 하기 일반식(Ia), (Ib), 및 (Ic)의 화합물, 또는 제약학적으로 허용되는 그의 염.상기 식 중에서, Z는 H, C1-C4알킬, 페닐, 치환된 페닐, 또는 페닐 고리가 치환될 수 있는 알킬페닐 치환체를 나타내고, R은 수소, 할로겐, C1-C4알킬, C1-C4알콕시, CF3, OCF3, OH, NO2또는 CN을 나타내고, B는 수소 C1-C4알킬, 치환될 수 있는 알킬페닐 또는 -CH2-COR2를 나타내고, X는 CO 또는 SO2를 나타내고, A는으로 구성되는 군으로부터 선택된 치환체를 나타내며, L은 수소, 할로겐, C1-C4알킬, C1-C4알콕시, CF3, OCF3, OH, NO2, NH2, 알킬페닐, 아세틸옥시 또느 CN으로 이루어진 군으로부터 선택된 치환체를 나타내고, R1, R2, 및 D는 각각 독립적으로 -OH, -OR3, -NR4R5, -OCH2OR3및 -O-(CH2)m-NR6R7(여기서 m은 1-4의 정수임)로 구성된 군으로부터 선택된 치환체를 나타내고, R3은 C1-C4알킬, 페닐, 치환된 페닐 또는 페닐-리가 치환될 수 있는 알킬페닐 치환체를 나타내고, R4및 R5은 각가 독립적으로 수소 또는 C1-C4알킬을 나타내고, R6및 R7는 각각 독립적으로 수소 또는 C1-C4알킬을 나타내거나 또는 R6및 R7이 인접한 질소 원자와 함께 피페리디노기, 모르폴리노기 또는 피롤리디노기를 형성하며, 단, 1) R, Z, B가 수소이고, R1은 OR3(R3은 에틸임)이고, X가 CO이면, L은 수소가 아니고, 2) X가 SO2이고, R 및 B가 수소이고, Z가 메틸이면, L은 파라 NO2또는 파라메틸이 아니고, 3) X가 SO2이고, R 및 B가 수소이고, Z가 H이면, L은 파라 C1이 아니고, 4) X가 SO2이면, A는 C(O)-D 또는 테트라졸이 될 수 없다.
- 제1항에 있어서, 하기 일반식(Ia)의 화합물.
- 제1항에 있어서, 하기 일반식(Ib)의 화합물.
- 제1항에 있어서, 하기 일반식(Ic)의 화합물.
- 제1항에 있어서, A가인 화합물.
- 제1항에 있어서, A가인 화합물.
- 제1항에 있어서, A가인 화합물.
- 제1항에 있어서, A가인 화합물.
- 제1항에 있어서, A가인 화합물.
- 제1항에 있어서, B가 C1-C4알킬, 치환될 수 있는 알킬페닐, -CH2-COR2인 화합물.
- 제1항에 있어서, X가 CO인 화합물.
- 제1항에 있어서, X가 SO2인 화합물.
- 제1항에 있어서, R은 4,6-, 또는 5,6-디클로로-인 화합물.
- 제1항에 있어서, R이 6-클로로-인 화합물.
- 제1항에 따르는 화합물 길항적 유효량을 그를 필요로 하는 환자에게 투여하는 것으로 이루어진 NMDA수용체 착물에 미치는 흥분성 아미노산의 효과를 길항시키는 방법.
- 제1항에 따르는 화합물 항간질 유효량을 그를 필요로 하는 환자에게 투여하는 것으로 이루어진 간질의 치료방법.
- 제1항에 따르는 화합물 유효량을 그를 필요로 하는 환자에게 투여하는 것으로 이루어진 신경 변성의 치료방법.
- 제1항에 따르는 화합물 유효량을 그를 필요로 하는 환자에게 투여하는 것으로 이루어진 대뇌 조직의 허혈/저산소증/저혈당성 손상을 예방하는 방법.
- 제1항에 따르는 화합물 항불안 유효량을 그를 필요로 하는 것으로 이루어진 불안증의 치료 방법.
- 제1항에 따르는 화합물 유효량을 그를 필요로 하는 환자에게 투여하는 것으로 이루어진 진통 효과의 생성 방법.
- 제1항에 따르는 화합물을 제약학적으로 허용할 수 있는 담체와 함께 함유하는 제약 조성물.
- (A) 일반식 (Ia)의 화합물을 얻기 위해 하기 반응도식 I에 나타낸 반응을 수행하거나,(B) 일반식(Ia)의 화합물을 얻기 위해 하기 반응도식 Ⅱ에 나타낸 반응을 수행하거나,(C) 일반식(Ia)의 화합물을 얻기 위해 하기 반응도식 Ⅲ에 나타낸 반응을 수행하거나,(D) 일반식(Ia)의 화합물을 얻기 위해 하기 반응도식 Ⅳ에 나타낸 반응을 수행하거나,(F) 일반식(Ib)의 화합물을 얻기 위해 하기 반응도식 Ⅴ에 나타낸 반응을 수행하거나,(G) 일반식(Ic)의 화합물을 얻기 위해 하기 반응도식 Ⅵ에 나타낸 반응을 수행하거나,(H) 청구 범위 또는 명세서에 기재된 반응도식들의 방법 또는 변형방법을 수행하는 것으로 이루어진 하기 일반식(Ia), (Ib) 및 (Ic)의 화합물 또는 제약학적으로 허용되는 그의 염의 제조방법.상기식 중에서, Z는 H, C1-C4알킬, 페닐, 치환된 페닐, 또는 페닐 고리가 치환될 수 있는 알킬페닐 치환체를 나타내고, R은 수소, 할로겐, C1-C4알킬, C1-C4알콕시, CF3, OCF3, OH, NO2또는 CN을 나타내고, B는 수소, C1-C4알킬, 치환될 수 있는 알킬페닐 또는 -CH2-COR2를 나타내고, X는 CO 또는 SO2를 나타내고, A는으로 구성된 군으로부터 선택된 치환체를 나타내며, L은 수소, 할로겐, C1-C4알킬, C1-C4알콕시, CF3, OCF3, OH, NO2, NH2, 알킬페닐, 아세틸옥시 또는 CN으로 이루어진 군으로부터 선택된 치환체를 나타내고, R1, R2및 D는 각각 독립적으로 -OH, -OR3, -NR4R5, -OCH2OR3및 -O-(CH2)m-NR6R7(여기서 m은 1-4의 정수임)로 구성된 군으로부터 선택된 치환체를 나타내고, R3은 C1-C4알킬, 페닐, 치환된 페닐 또는 페닐 고리가 치환될 수 있는 알킬페닐 치환체를 나타내고, R4및 R5는 각각 독립적으로 수소 또는 C1-C4알킬을 나타내고, R6및 R7는 각각 독립적으로 수소 또는 C1-C4알킬을 나타내거나, 또는 R6및 R7이 인접한 질소 원자와 함께 피페리디노기, 모르폴리노기 또는 피롤리디노기를 형성하며, 단, 1) R, Z, B가 수소이고, R1은 OR3(R3은 에틸임)이고, X가 CO이면, L은 수소가 아니고, 2) X가 SO2이고, R 및 B가 수소이고, Z가 메틸이면 L은 파라 NO2또는 파라 메틸이 아니고, 3) X가 SO2이고, R 및 B가 수소이고, Z가 H이면, L은 파라 C1이 아니고, 4) X가 SO2이면, A는 C(O)-D 또는 테트라졸이 될 수 없다.
- 제2항에 있어서, B가 CH3이고, R이 4,6-디클로이고, Z가 H이고, R이 H이고, A가 C6H5인 화합물.
- 제1항의 화합물의 의약으로서의 용도.
- 제1항의 화합물의 NMDA 수용체 착물에 미치는 흥분성 아미노산의 효과를 길항하기 위한 의약으로서의 용도.
- 제1항의 화합물의 간질 또는 허혈 치료를 위한 의약으로서의 용도.※참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60845790A | 1990-11-02 | 1990-11-02 | |
| US608,457 | 1990-11-02 | ||
| US76753191A | 1991-10-02 | 1991-10-02 | |
| US767531 | 1991-10-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR920009796A true KR920009796A (ko) | 1992-06-25 |
| KR100220882B1 KR100220882B1 (ko) | 1999-09-15 |
Family
ID=27085774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019910019414A Expired - Lifetime KR100220882B1 (ko) | 1990-11-02 | 1991-11-01 | 3-아미도인돌릴 유도체 |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0483881B1 (ko) |
| JP (1) | JP3168565B2 (ko) |
| KR (1) | KR100220882B1 (ko) |
| AT (1) | ATE162519T1 (ko) |
| AU (1) | AU641052B2 (ko) |
| CA (1) | CA2054339C (ko) |
| DE (1) | DE69128764T2 (ko) |
| DK (1) | DK0483881T3 (ko) |
| ES (1) | ES2113359T3 (ko) |
| FI (1) | FI102676B (ko) |
| GR (1) | GR3026349T3 (ko) |
| HU (1) | HU214597B (ko) |
| IE (1) | IE913834A1 (ko) |
| IL (1) | IL99908A (ko) |
| NO (1) | NO177139C (ko) |
| NZ (1) | NZ240380A (ko) |
| PT (1) | PT99400B (ko) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4242675A1 (de) * | 1992-12-17 | 1994-06-23 | Basf Ag | Neue Hydroxyiminoalkylindolcarbonsäure-Derivate, ihre Herstellung und Verwendung |
| GB9311948D0 (en) * | 1993-06-10 | 1993-07-28 | Zeneca Ltd | Substituted nitrogen heterocycles |
| TW280819B (ko) * | 1993-11-17 | 1996-07-11 | Sumitomo Pharma | |
| US5801168A (en) * | 1994-06-09 | 1998-09-01 | Zeneca Limited | Substituted nitrogen heterocycles |
| UA82827C2 (en) | 2000-12-18 | 2008-05-26 | Inhibitors against the production and release of inflammatory cytokines | |
| RS51865B (sr) * | 2002-01-29 | 2012-02-29 | Laboratoires Serono Sa. | Supstituisani derivati metilen amida kao modulatori protein tirozin fosfataze (ptp) |
| GB0217920D0 (en) * | 2002-04-23 | 2002-09-11 | Aventis Pharm Prod Inc | Interleukin-4 Gene Expression inhibitors |
| US20060122243A1 (en) | 2002-06-06 | 2006-06-08 | Susumu Muto | Antiallergic |
| KR20110028554A (ko) | 2002-06-06 | 2011-03-18 | 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 | Ｏ-치환 히드록시아릴 유도체 |
| WO2003103657A1 (ja) * | 2002-06-11 | 2003-12-18 | 株式会社医薬分子設計研究所 | 神経変性疾患治療剤 |
| MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| ATE405549T1 (de) | 2004-06-18 | 2008-09-15 | Biolipox Ab | Zur behandlung von entzündungen geeignete indole |
| EP1794143B8 (en) * | 2004-08-24 | 2008-12-24 | Janssen Pharmaceutica N.V. | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents |
| EA200701504A1 (ru) | 2005-01-19 | 2008-02-28 | Биолипокс Аб | Индолы, пригодные для лечения воспалений |
| AU2006249577A1 (en) | 2005-05-20 | 2006-11-30 | Janssen Pharmaceutica N.V. | Process for preparation of sulfamide derivatives |
| WO2006127945A1 (en) | 2005-05-26 | 2006-11-30 | Neuron Systems | Compositions and methods of treating retinal disease |
| US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
| US8492431B2 (en) | 2005-12-19 | 2013-07-23 | Janssen Pharmaceutica, N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
| US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
| WO2007137167A2 (en) | 2006-05-19 | 2007-11-29 | Janssen Pharmaceutica N.V. | Co-therapy for the treatment of epilepsy |
| EA018567B1 (ru) | 2008-06-23 | 2013-08-30 | Янссен Фармацевтика Нв | Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида |
| US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
| CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
| CN105073714A (zh) | 2012-12-20 | 2015-11-18 | 奥尔德拉医疗公司 | 迫位原醇 |
| CA3195807A1 (en) | 2013-01-23 | 2014-07-31 | Aldeyra Therapeutics, Inc. | Toxic aldehyde related diseases and treatment |
| US10111862B2 (en) | 2013-01-25 | 2018-10-30 | Aldeyra Therapeutics, Inc. | Traps in the treatment of macular degeneration |
| EP3337486B1 (en) | 2015-08-21 | 2024-04-03 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
| MX2018013472A (es) | 2016-05-09 | 2019-02-28 | Aldeyra Therapeutics Inc | Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares. |
| AU2018234919A1 (en) | 2017-03-16 | 2019-09-19 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| MX2020003425A (es) | 2017-10-10 | 2020-07-29 | Aldeyra Therapeutics Inc | Tratamiento de trastornos inflamatorios. |
| US12006298B2 (en) | 2018-08-06 | 2024-06-11 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| JP2022530967A (ja) | 2019-05-02 | 2022-07-05 | アルデイラ セラピューティクス， インコーポレイテッド | 多形化合物およびその使用 |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| JP2023526016A (ja) | 2020-05-13 | 2023-06-20 | アルデイラ セラピューティクス， インコーポレイテッド | 医薬製剤およびその使用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60123485A (ja) * | 1983-12-08 | 1985-07-02 | Yoshitomi Pharmaceut Ind Ltd | インド−ル−３−カルボキサミド誘導体 |
| US4675332A (en) * | 1984-12-10 | 1987-06-23 | Warner-Lambert Company | Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents |
| IL84796A (en) * | 1986-12-17 | 1992-03-29 | Merck Frosst Canada Inc | Substituted n-benzyl-indoles and pharmaceutical compositions containing them |
-
1991
- 1991-10-28 AU AU86760/91A patent/AU641052B2/en not_active Expired
- 1991-10-28 CA CA002054339A patent/CA2054339C/en not_active Expired - Lifetime
- 1991-10-29 NZ NZ240380A patent/NZ240380A/en not_active IP Right Cessation
- 1991-10-30 IL IL9990891A patent/IL99908A/en not_active IP Right Cessation
- 1991-10-31 FI FI915146A patent/FI102676B/fi not_active IP Right Cessation
- 1991-10-31 PT PT99400A patent/PT99400B/pt not_active IP Right Cessation
- 1991-10-31 JP JP32157391A patent/JP3168565B2/ja not_active Expired - Lifetime
- 1991-11-01 IE IE383491A patent/IE913834A1/en not_active IP Right Cessation
- 1991-11-01 HU HU913454A patent/HU214597B/hu unknown
- 1991-11-01 KR KR1019910019414A patent/KR100220882B1/ko not_active Expired - Lifetime
- 1991-11-01 NO NO914300A patent/NO177139C/no not_active IP Right Cessation
- 1991-11-04 ES ES91118738T patent/ES2113359T3/es not_active Expired - Lifetime
- 1991-11-04 DK DK91118738.3T patent/DK0483881T3/da active
- 1991-11-04 EP EP91118738A patent/EP0483881B1/en not_active Expired - Lifetime
- 1991-11-04 AT AT91118738T patent/ATE162519T1/de not_active IP Right Cessation
- 1991-11-04 DE DE69128764T patent/DE69128764T2/de not_active Expired - Lifetime
-
1998
- 1998-03-13 GR GR980400534T patent/GR3026349T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP3168565B2 (ja) | 2001-05-21 |
| IE913834A1 (en) | 1992-05-22 |
| ES2113359T3 (es) | 1998-05-01 |
| HU214597B (hu) | 1998-04-28 |
| DE69128764D1 (de) | 1998-02-26 |
| NO177139B (no) | 1995-04-18 |
| PT99400B (pt) | 1999-04-30 |
| NO177139C (no) | 1995-07-26 |
| HUT59668A (en) | 1992-06-29 |
| FI102676B1 (fi) | 1999-01-29 |
| DE69128764T2 (de) | 1998-06-04 |
| PT99400A (pt) | 1992-09-30 |
| CA2054339C (en) | 2002-12-24 |
| JPH0733737A (ja) | 1995-02-03 |
| AU8676091A (en) | 1992-05-07 |
| EP0483881B1 (en) | 1998-01-21 |
| FI102676B (fi) | 1999-01-29 |
| ATE162519T1 (de) | 1998-02-15 |
| KR100220882B1 (ko) | 1999-09-15 |
| EP0483881A1 (en) | 1992-05-06 |
| AU641052B2 (en) | 1993-09-09 |
| NO914300D0 (no) | 1991-11-01 |
| FI915146L (fi) | 1992-05-03 |
| NZ240380A (en) | 1994-05-26 |
| IL99908A (en) | 1995-10-31 |
| CA2054339A1 (en) | 1992-05-03 |
| HU913454D0 (en) | 1992-01-28 |
| NO914300L (no) | 1992-05-04 |
| IL99908A0 (en) | 1992-08-18 |
| GR3026349T3 (en) | 1998-06-30 |
| FI915146A0 (fi) | 1991-10-31 |
| DK0483881T3 (da) | 1998-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR920009796A (ko) | 3-아미도인돌릴 유도체 | |
| JP2001526269A5 (ko) | ||
| RU92004336A (ru) | Водорастворимые производные камптотецина, способ их получения, фармацевтическая композиция, способ ингибирования энзима топоизомеразы, промежуточные продукты | |
| ATE167186T1 (de) | Diphenylmethane derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen | |
| KR890701562A (ko) | 면역조절 아자스 피란류 | |
| RU2000127751A (ru) | Противоопухолевое средство | |
| RU95117068A (ru) | Антигипертриглицеридемическая композиция, способ ее получения, способ лечения или профилактики гипертриглицеридемии, применение соединений | |
| KR900015729A (ko) | 흥분성 아미노산 길항제 | |
| KR900018112A (ko) | 흥분성 아미노산 길항제 | |
| KR937000438A (ko) | 3-인돌릴 티오아세테이트 유도체 | |
| KR900004659A (ko) | α,α-이치환 N- 시클로알킬알킬 벤질아민, 이들의 제조 방법, 의약품으로서 이들의 용도 및 이들의 합성 중간체 | |
| KR920016418A (ko) | Nmda 길항제 | |
| KR940003953A (ko) | 1. 4-벤조디옥산 유도체 | |
| KR910018383A (ko) | 종양성 질환 치료용 엽산염 및 항엽산염과의 디플루오로글루 탐산 공역체 | |
| NO890440L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater. | |
| KR840006985A (ko) | N-치환플라본-8-카르복사미드유도체 및 그 제조방법 | |
| KR927003537A (ko) | 4, 5-사이클로알카노-3-벤즈아제핀-7-올 유도체 및 이의 용도 | |
| ZA911813B (en) | (benzhydryloxyethylpiperidyl)aliphatic acid derivatives and their use in the treatment of allergies and asthma | |
| ATE41659T1 (de) | Benzothiazepinderivate, verfahren zur herstellung und pharmazeutische zusammensetzungen. | |
| KR930703257A (ko) | 엔엠디에이(nmda) 길항제 | |
| KR960017669A (ko) | 양쪽성 3환식 화합물 | |
| KR960702438A (ko) | 3-(인돌-3-일)프로페노산 유도체 및 N-메틸-D-아스파르테이트 길항제로서의 이의 용도[3-(lndol-3-yl)propenoic acid derivatives and as NMDA antagonists] | |
| ES477257A1 (es) | Un procedimiento para preprarar derivados de isoquinoleina. | |
| KR880013896A (ko) | 벤조푸로[3,2-c]퀴놀린 화합물 | |
| KR950704322A (ko) | 스피로푸라논 유도체 및 그의 신경변성 질환 치료 용도(Spirofuranone Derivatives and Their Use in the Treatment of Neurodegenerative Disorders) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19911101 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19961026 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19911101 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 19981221 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 19990511 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 19990623 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 19990624 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20020619 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20030617 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20040617 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20050617 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20060619 Start annual number: 8 End annual number: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20070611 Start annual number: 9 End annual number: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20080530 Start annual number: 10 End annual number: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20090609 Start annual number: 11 End annual number: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20100610 Start annual number: 12 End annual number: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20110519 Year of fee payment: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20110519 Start annual number: 13 End annual number: 13 |
|
| EXPY | Expiration of term | ||
| PC1801 | Expiration of term |
Termination date: 20121009 Termination category: Expiration of duration |